Literature DB >> 18584117

Two-stage designs to identify the effects of SNP combinations on complex diseases.

Guolian Kang1,2, Weihua Yue3, Jifeng Zhang1, Marianne Huebner4, Handi Zhang3, Yan Ruan3, Tianlan Lu3, Yansu Ling3, Yijun Zuo4, Dai Zhang5.   

Abstract

The genetic basis of complex diseases is expected to be highly heterogeneous, with many disease genes, where each gene by itself has only a small effect. Based on the nonlinear contributions of disease genes across the genome to complex diseases, we introduce the concept of single nucleotide polymorphism (SNP) synergistic blocks. A two-stage approach is applied to detect the genetic association of synergistic blocks with a disease. In the first stage, synergistic blocks associated with a complex disease are identified by clustering SNP patterns and choosing blocks within a cluster that minimize a diversity criterion. In the second stage, a logistic regression model is given for a synergistic block. Using simulated case-control data, we demonstrate that our method has reasonable power to identify gene-gene interactions. To further evaluate the performance of our method, we apply our method to 17 loci of four candidate genes for paranoid schizophrenia in a Chinese population. Five synergistic blocks are found to be associated with schizophrenia, three of which are negatively associated (odds ratio, OR < 0.3, P < 0.05), while the others are positively associated (OR > 2.0, P < 0.05). The mathematical models of these five synergistic blocks are presented. The results suggest that there may be interactive effects for schizophrenia among variants of the genes neuregulin 1 (NRG1, 8p22-p11), G72 (13q34), the regulator of G-protein signaling-4 (RGS4, 1q21-q22) and frizzled 3 (FZD3, 8p21). Using synergistic blocks, we can reduce the dimensionality in a multi-locus association analysis, and evaluate the sizes of interactive effects among multiple disease genes on complex phenotypes.

Entities:  

Mesh:

Year:  2008        PMID: 18584117     DOI: 10.1007/s10038-008-0307-x

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  16 in total

1.  Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions.

Authors:  Lance W Hahn; Marylyn D Ritchie; Jason H Moore
Journal:  Bioinformatics       Date:  2003-02-12       Impact factor: 6.937

2.  Rapid simulation of P values for product methods and multiple-testing adjustment in association studies.

Authors:  S R Seaman; B Müller-Myhsok
Journal:  Am J Hum Genet       Date:  2005-01-11       Impact factor: 11.025

3.  An entropy-based approach for testing genetic epistasis underlying complex diseases.

Authors:  Guolian Kang; Weihua Yue; Jifeng Zhang; Yuehua Cui; Yijun Zuo; Dai Zhang
Journal:  J Theor Biol       Date:  2007-10-06       Impact factor: 2.691

4.  Association of G72/G30 polymorphisms with early-onset and male schizophrenia.

Authors:  Weihua Yue; Zhonghua Liu; Guolian Kang; Jun Yan; Fulei Tang; Yan Ruan; Jifeng Zhang; Dai Zhang
Journal:  Neuroreport       Date:  2006-12-18       Impact factor: 1.837

5.  The future of genetic studies of complex human diseases.

Authors:  N Risch; K Merikangas
Journal:  Science       Date:  1996-09-13       Impact factor: 47.728

6.  Who's afraid of epistasis?

Authors:  W N Frankel; N J Schork
Journal:  Nat Genet       Date:  1996-12       Impact factor: 38.330

7.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer.

Authors:  M D Ritchie; L W Hahn; N Roodi; L R Bailey; W D Dupont; F F Parl; J H Moore
Journal:  Am J Hum Genet       Date:  2001-06-11       Impact factor: 11.025

8.  Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis.

Authors:  Julie E Goodman; Leah E Mechanic; Brian T Luke; Stefan Ambs; Stephen Chanock; Curtis C Harris
Journal:  Int J Cancer       Date:  2006-04-01       Impact factor: 7.396

9.  Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects.

Authors:  Weihua Yue; Guolian Kang; Yanbo Zhang; Mei Qu; Fulei Tang; Yonghua Han; Yan Ruan; Tianlan Lu; Jifeng Zhang; Dai Zhang
Journal:  Neurosci Lett       Date:  2007-01-30       Impact factor: 3.046

Review 10.  Genes for schizophrenia? Recent findings and their pathophysiological implications.

Authors:  Paul J Harrison; Michael J Owen
Journal:  Lancet       Date:  2003-02-01       Impact factor: 79.321

View more
  2 in total

1.  An Information Theoretical Study of the Epistasis Between the CNR1 1359 G/A Polymorphism and the Taq1A and Taq1B DRD2 Polymorphisms: Assessing the Susceptibility to Cannabis Addiction in a Turkish Population.

Authors:  Aysun Baransel Isir; Cesur Baransel; Muradiye Nacak
Journal:  J Mol Neurosci       Date:  2016-01-30       Impact factor: 3.444

Review 2.  Candidate genes and their interactions with other genetic/environmental risk factors in the etiology of schizophrenia.

Authors:  K M Prasad; M E Talkowski; K V Chowdari; L McClain; R H Yolken; V L Nimgaonkar
Journal:  Brain Res Bull       Date:  2009-09-01       Impact factor: 4.077

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.